About
Contact
Subscribe
e-Edition

Make Home Page

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Facebook
Twitter

- Site search

Home
News
Sports
- Local Sports
- National Sports
Business
Opinion
A & E
Life
Features & Magazines
Classifieds
Weather
Obituaries
Parcel Pickup

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Charles River Laboratories International, Inc. Common Stock (NY:CRL)

216.82 +0.71 (+0.33%)

Streaming Delayed Price Updated: 9:54 AM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Charles River Laboratories International, Inc. Common Stock

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Charles River Laboratories to Present at Baird and Morgan Stanley Conferences

September 08, 2022

From Charles River Laboratories International, Inc.

Via Business Wire

Charles River and Cure AP-4 Announce Gene Therapy Manufacturing Collaboration

September 06, 2022

From Charles River Laboratories International, Inc.

Via Business Wire

Expert Ratings for Charles River ↗

August 25, 2022

Within the last quarter, Charles River (NYSE:CRL) has observed the following analyst ratings:

Via Benzinga

Charles River Laboratories Expands Contract Vivarium Space on West Coast

August 23, 2022

From Charles River Laboratories International, Inc.

Via Business Wire

Recap: Charles River Q2 Earnings ↗

August 03, 2022

Charles River (NYSE:CRL) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022 ↗

August 25, 2022

Upgrades

Via Benzinga

NexImmune Price Target Cut By 75%, Plus Wells Fargo Lowers PT Price Target On These Stocks ↗

August 16, 2022

Raymond James cut the price target for NexImmune, Inc. (NASDAQ: NEXI) from $12 to $3. NexImmune shares rose 2.4% to $1.29 in pre-market trading.

Via Benzinga

Analyst Ratings for Charles River ↗

May 24, 2022

Within the last quarter, Charles River (NYSE:CRL) has observed the following analyst ratings:

Via Benzinga

Charles River: Q1 Earnings Insights ↗

May 04, 2022

Charles River (NYSE:CRL) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Charles River Laboratories is First CDMO in North America to Receive EMA Approval to Commercially Produce an Allogeneic Cell Therapy Drug Product

August 09, 2022

From Charles River Laboratories, International Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2022 ↗

August 04, 2022

Upgrades

Via Benzinga

AMD, SolarEdge Technologies And Some Other Big Stocks Moving Lower On Wednesday ↗

August 03, 2022

Rocky Brands, Inc. (NASDAQ: RCKY) dipped 21.6% to $26.62 after the company reported worse-than-expected Q2 EPS results.

Via Benzinga

Charles River Laboratories Announces Second-Quarter 2022 Results

August 03, 2022

From Charles River Laboratories International, Inc.

Via Business Wire

'I'm Going To Have To Say Avoid It': Jim Cramer Urges Waiting Before Buying This Tech Stock ↗

August 02, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying Charles River Laboratories International Inc (NYSE: CRL).

Via Benzinga

Where Charles River Stands With Analysts ↗

July 14, 2022

Over the past 3 months, 5 analysts have published their opinion on Charles River (NYSE:CRL) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

Charles River Laboratories Schedules Second-Quarter 2022 Earnings Release and Conference Call

July 11, 2022

From Charles River Laboratories International, Inc.

Via Business Wire

Charles River Laboratories Announces Opening of U.K. Manufacturing Facility

June 28, 2022

From Charles River Laboratories International, Inc.

Via Business Wire

Charles River and Ziphius Vaccines Collaborate to Manufacture saRNA-Based Vaccine

June 23, 2022

From Charles River Laboratories International, Inc.

Via Business Wire

Charles River and ASC Therapeutics to Scale Manufacturing of Second-Generation Gene Therapy for Hemophilia A

June 13, 2022

From Charles River Laboratories International, Inc.

Via Business Wire

Charles River Laboratories to Participate in Jefferies and William Blair Conferences

June 06, 2022

From Charles River Laboratories International, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2022 ↗

May 24, 2022

Upgrades

Via Benzinga

Charles River Laboratories Announces First-Quarter 2022 Results

May 04, 2022

From Charles River Laboratories International, Inc.

Via Business Wire

Preview: Charles River's Earnings ↗

May 03, 2022

Charles River (NYSE:CRL) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Charles River...

Via Benzinga

Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

April 27, 2022

From Charles River Laboratories International, Inc.

Via Business Wire

3 Top S&P 500 Stock Market Gainers Today: Coronavirus Vaccine Maker Moderna Jumps ↗

April 25, 2022

Moderna led big-cap winners Monday. Oil services giants were losers.

Via Investor's Business Daily

Wells Fargo Maintains Overweight Rating for Charles River: Here's What You Need To Know ↗

April 25, 2022

Wells Fargo has decided to maintain its Overweight rating of Charles River (NYSE:CRL) and lower its price target from $390.00 to $325.00. Shares of Charles River are trading down 7.96% over the last 24...

Via Benzinga

What 6 Analyst Ratings Have To Say About Charles River ↗

April 25, 2022

Analysts have provided the following ratings for Charles River (NYSE:CRL) within the last quarter:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022 ↗

April 25, 2022

Via Benzinga

10 Biggest Price Target Changes For Monday ↗

April 25, 2022

Keybanc cut Salesforce, Inc. (NYSE: CRM) price target from $281 to $223. Salesforce shares fell 1.1% to $169.60 in pre-market trading.

Via Benzinga

Charles River Laboratories Schedules First-Quarter 2022 Earnings Release and Conference Call

April 13, 2022

From Charles River Laboratories International, Inc.

Via Business Wire

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Sports
Opinion
Photo Galleries
Videos
Local Events
Classifieds
Obituaries

Services

About
Contact
Personnel
Advertise
Subscription Services
Promote Your Event
Dealer Locations
Email Alerts
Submission Forms

Contact Information

chroniclejournal.com
75 S. Cumberland Street
Thunder Bay, ON P7B 1A3
Phone: 807 343 6200
Email: circulation@chroniclejournal.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Charles River Laboratories International, Inc. Common Stock (NY:CRL)

All News about Charles River Laboratories International, Inc. Common Stock

Sections

Services

Contact Information

Follow Us